Conversation with The Cancer Letter Tom Loughran tells us how he got UVA over the hump to comprehensive designation November 19, 2021Vol.47 No.43By Paul Goldberg
Cancer History ProjectConversation with The Cancer LetterFree Patricia Ganz on how survivorship went from being an outlier to the mainstream November 19, 2021Vol.47 No.43By Alexandria Carolan
Conversation with The Cancer LetterFreeHealth Equity FDA’s Lola Fashoyin-Aje: Stop getting stuck on the “risks” of diversity in drug development, it’s time to fix disparities in access November 12, 2021Vol.47 No.42By Matthew Bin Han Ong
Conversation with The Cancer LetterFreeHealth Equity NCTN group chairs, experts: Diverse representation of minorities in clinical trials and drug development saves lives November 12, 2021Vol.47 No.42By Matthew Bin Han Ong
Conversation with The Cancer Letter Eric Winer talks about his vision for Yale Cancer Center—and his return to New Haven October 29, 2021Vol.47 No.40By Paul Goldberg
Conversation with The Cancer Letter Danny Milner: mRNA vaccines may become a viable treatment for cancer because of COVID-19 pandemic October 29, 2021Vol.47 No.40By Alice Tracey
Conversation with The Cancer Letter Michelle Le Beau: CPRIT will be “looking at everything” through a health equity lens in awarding billions of dollars in grants October 22, 2021Vol.47 No.39By Matthew Bin Han Ong
Cancer History ProjectConversation with The Cancer LetterFree Susan Love on breast cancer activism in the 1990s October 22, 2021Vol.47 No.39By Alexandria Carolan
Conversation with The Cancer Letter FDA’s review of “dangling indications” continues beyond PD-1 and PD-L1 drugs October 15, 2021Vol.47 No.38By Paul Goldberg
Conversation with The Cancer LetterFree David Weinberg: Only NCI has the capacity to answer public health question on managing pancreatic cysts October 08, 2021Vol.47 No.37By Paul Goldberg
